research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
Search
for
Sort by
Research
600-630 / 1000+ results 
research Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens
Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.
research Association of vitamin D level with alopecia areata
Vitamin D levels are not linked to alopecia areata.
research Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research Local Corticosteroids for Alopecia Areata: A Narrative Review
Local corticosteroids can help with alopecia areata, but hair loss often returns after stopping treatment.
research Platelet-rich plasma in alopecia areata: intradermal injection versus topical application with transepidermal delivery via either fractional carbon dioxide laser or microneedling
Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Sequential cyclic changes of hair roots revealed by dermoscopy demonstrate a progressive mechanism of diffuse alopecia areata over time
Dermoscopy shows that diffuse alopecia areata progresses through specific hair growth stages.
research Using automated microneedling with platelet rich plasma for treating cicatricial alopecia, recalcitrant alopecia areata and traction alopecia, case report
Microneedling with platelet-rich plasma can improve different types of hair loss.
research Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research The Relationship Between ABO And Rh Blood Groups With Alopecia Areata
AB+ blood group is more common in alopecia areata patients.
research Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination
COVID-19 may trigger alopecia areata, but more research is needed.
research The Ratio of Typical Clubbing in Pulled-Out Hairs as a Useful Marker in Predicting the Course of Alopecia Areata
Examining hair shape can help predict Alopecia Areata's progression.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research Metabolic syndrome in alopecia areata: an observational study at a tertiary care center
There is no significant link between metabolic syndrome and alopecia areata.
research Retrospective Analysis of Systemic Corticosteroids for Alopecia Areata in Pediatric Patients
Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
research Immunotherapy for resistant and/or severe alopecia areata in a university hospital setting in Northern Mexico
Immunotherapy can help treat severe alopecia areata.
research Monitoring Response to Platelet-Rich Plasma in Patients with Alopecia Areata with Optical Coherence Tomography: A Case Series
Platelet-Rich Plasma treatment improved hair growth and reduced inflammation in patients with patchy hair loss, but not in total hair loss, and Optical Coherence Tomography was useful in tracking this progress.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
research Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
Baricitinib effectively regrows hair in severe alopecia areata cases.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA
Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.